Compare actual RU58841 and pyrilutamide research, including 2026 human data, trial limitations, and why no head-to-head winner is established.
Pyrilutamide has a more substantial publicly reported clinical development program, but the evidence reviewed here does not establish that it works better than RU58841. We found no randomized human trial directly comparing the two. Claims that RU is stronger or pyrilutamide is safer therefore go beyond these sources.
Evidence checked September 16, 2026. This comparison distinguishes published research, trial registrations, and sponsor announcements. It does not provide a self-treatment protocol.
| Question | RU58841 | Pyrilutamide, also called KX-826 |
|---|---|---|
| Are human studies available? | Historical PSK-3841 trial registrations and a small 2026 metabolism study | Multiple clinical studies, including sponsor-reported phase III results |
| Does the cited evidence establish superiority over the other compound? | No | No |
| Is there a relevant limitation? | Registered hair trials do not supply results in the records reviewed; the metabolism study did not measure regrowth | The earlier and newer phase III studies had different outcomes; announcements are less complete than full trial reports |
| Can a seller's bottle be assumed equivalent to a trial formulation? | No such equivalence is established here | No such equivalence is established here |
The study details and sources follow. A registration documents a study's existence and design; it does not, by itself, supply a successful result.
A frequently cited 1997 experiment used scalp tissue from men transplanted onto mice. Researchers studied hair production in those grafts. The presence of human tissue does not make this a trial of hair treatment in human participants. Its findings cannot establish a human regrowth rate or long-term safety profile. Original study abstract.
RU58841 is also known as PSK-3841. Two historical human studies are registered under that name: a four-week safety and tolerance study and a six-month, randomized, vehicle-controlled hair-growth study. Both records say completed, but neither supplies results in its results/publications section as checked for this update. It would be inaccurate to say that human trials never existed, or to treat their completion as proof of efficacy. Four-week registry record, six-month registry record.
A paper published August 19, 2026 adds a different kind of human evidence. Six healthy men received one topical application, followed by blood-spot and urine sampling. Researchers detected RU58841 in blood samples, demonstrating systemic exposure under those conditions. They found no change in the urinary steroid-profile markers assessed for antidoping analysis. That narrow result does not establish general endocrine safety, safety with repeated use, or hair regrowth. The study was designed around metabolism and detection, not treatment effectiveness. It also identifies the PSK-3841 synonym. Okutan and colleagues, full study.
Kintor's earlier Chinese phase III study enrolled 740 men and evaluated a 0.5% formulation over 24 weeks. Its 2023 annual report states that hair counts improved from baseline, but the difference from vehicle was not statistically significant. Improvement within a treatment group is not the same finding as improvement beyond its control group. Kintor 2023 annual report, page 19.
On March 18, 2026, Kintor announced positive top-line results from a newer phase III stage involving 666 men in China. At 24 weeks, reported changes in target-area non-vellus hair count were:
| Trial group | Increase from baseline, hairs/cm² | Difference from vehicle, hairs/cm² |
|---|---|---|
| 1.0% formulation, twice daily | 15.33 | 10.65 |
| 0.5% formulation, twice daily | 14.46 | 9.78 |
| Vehicle | 4.68 | — |
The sponsor reported both active-versus-vehicle comparisons as statistically significant and reported no drug-related serious adverse events. These are sponsor-reported results for the studied formulations and population; the concentrations describe trial arms, not instructions for use. March 2026 announcement.
Kintor subsequently reported presentation of the final analysis at the May 2026 World Congress for Hair Research. That announcement does not contain the complete analysis or turn the study into a comparison with RU58841. June 2026 update.
Commercial availability also needs careful interpretation. In its August 19, 2026 interim results, Kintor described existing cosmetic sales separately from drug development and said it planned a Chinese new-drug application in the second half of 2026. An application plan or a cosmetic listing is not evidence of an approved drug indication. August 2026 interim report, including pages 2 and 34.
A useful comparison would assign comparable participants to the two treatments, measure the same outcomes over the same period, and report withdrawals and adverse events. Comparing photographs from people using different combinations cannot isolate either compound's contribution. Different lighting, hair length, concurrent treatments, and selective reporting leave several explanations for a visible change.
Likewise, a positive trial against vehicle cannot establish superiority to a treatment that was not in that trial. The supported conclusion is about the evidence available, not a ranking of products to buy.
For a personal hair-loss decision, take the relevant trial or registry record to a dermatologist and ask whether its participants, outcome, and formulation apply to your situation. Record which claims remain unanswered rather than converting them into a dosing experiment.
If the unresolved question concerns the contents of a product, our peptide certificate-of-analysis guide explains the distinction between identity, purity, and quantity. Its analytical principles are useful context, but a COA does not establish clinical effectiveness or make an experimental treatment safe.
This article contains no affiliate purchase links. The comparison was revised to remove unsupported superiority claims and self-dosing advice; its original URL and publication date are retained.
Powered by BTST